7860.Two

The company maintains a strong liquidity position, with cash and equivalents amounting to TWD 407.15 million, representing 36.5% of total assets. The debt-to-equity ratio of 0.07 indicates a conservative capital structure, with long-term debt at TWD 75 million compared to total equity of TWD 111.47 billion. The enterprise value to revenue ratio of 1.72 suggests a relatively low valuation multiple, supported by a market cap of TWD 17.89 billion and total liabilities of TWD 28.86 billion.

Profitability metrics show a healthy operating cash flow of TWD 109.10 million, with capital expenditures at TWD -17.45 million, indicating a net cash inflow from operations. The company's return on invested capital (ROIC) and operating margins are not explicitly provided, but the low debt load and strong cash position suggest a stable financial foundation. These metrics align with industry norms for pharmaceutical firms, which typically prioritize R&D investment and long-term asset management.

The company's revenue is not segmented by product or geography in the provided data, but the single revenue line item of TWD 845.19 million suggests a concentrated business model. The absence of geographic or segment breakdown limits visibility into diversification risks, though the low debt and high cash reserves mitigate liquidity concerns.

Looking ahead, the company's growth trajectory is supported by a stable operating cash flow and low capital expenditure requirements. The current fiscal year is expected to show continued revenue stability, with no immediate signs of contraction. The next fiscal year outlook is not quantified, but the company's financial flexibility positions it to invest in R&D or strategic acquisitions if needed.

Risk factors are minimal, with low liquidity and dilution risk scores. No immediate filing-based flags were detected, and the company's capital structure remains stable with no near-term pressure for equity issuance. The dilution potential is low, with basic and diluted shares outstanding aligned at 32 million.

Recent events include the latest financial filing, which confirms the company's strong liquidity and conservative leverage. No material changes in business strategy or regulatory exposure were disclosed in the available data. The company's financial health remains consistent with its historical performance, with no significant deviations in operating cash flow or capital structure.